Megan McCarthy
Yale University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Megan McCarthy.
Fetal Diagnosis and Therapy | 2017
Karen Archabald; Irina A. Buhimschi; Mert Bahtiyar; Antonette T. Dulay; Sonya S. Abdel-Razeq; Christian M. Pettker; Heather S. Lipkind; John Hardy; Megan McCarthy; Guomao Zhao; Vineet Bhandari; Catalin S. Buhimschi
Background: To improve neonatal outcomes in pregnancies at heightened risk for early-onset neonatal sepsis (EONS), there is a need to identify fetuses that benefit from expectant management as opposed to early delivery. Detectable haptoglobin and haptoglobin-related protein (Hp&HpRP switch-on status) in cord blood has been proposed as a biomarker of antenatal exposure to intra-amniotic infection and/or inflammation (IAI), an important determinant of EONS. Subjects and Methods: We analyzed 185 singleton newborns delivered secondary to preterm premature rupture of membranes (PPROM). In 123 cases, amniocentesis was performed to exclude amniotic fluid (AF) infection. Delivery was indicated for 61 cases with confirmed infection. Women without AF infection (n = 62) and those without amniocentesis (n = 62) were managed expectantly. Interleukin 6 and Hp&HpRP switch-on status were evaluated by ELISA and Western blot. Newborns were followed prospectively for short-term outcomes until hospital discharge or death. Results: Newborns exposed antenatally to IAI had an increased risk of adverse neonatal outcome [OR: 3.0 (95% CI: 1.15-7.59)]. Increasing gestational age [OR: 0.61 (95% CI: 0.52-0.70)] and management with amniocentesis [OR: 0.37 (95% CI: 0.14-0.95)] lowered the newborns risk of developing adverse outcomes. Discussion: In the setting of PPROM and IAI, early delivery benefits a select subgroup of fetuses that have not yet progressed to Hp&HpRP switch-on status.
The Journal of Clinical Endocrinology and Metabolism | 2016
John Hardy; Irina A. Buhimschi; Megan McCarthy; Guomao Zhao; Christine Laky; Lydia Shook; Catalin S. Buhimschi
CONTEXT Microbial invasion of the amniotic fluid (AF) cavity stimulates an inflammatory response that involves activin-A, a pleiotropic mediator member of the TGFβ superfamily involved in connective tissue remodeling. The role of AF follistatin, a natural inhibitor of activin-A, in inflammation-induced preterm birth (PTB), has yet to be determined. OBJECTIVE The objective of the study was to investigate the relationships between AF activin-A and follistatin in physiological gestation and in pregnancies complicated by PTB and to evaluate a possible role played by the activin-A-follistatin balance in processes leading to PTB and preterm premature rupture of membranes (PPROM). STUDY DESIGN The AF levels of total activin-A and follistatin were immunoassayed in 168 women with a normal pregnancy outcome or PTB with and without intraamniotic inflammation or PPROM. The impact of the activin-A-follistatin imbalance on PTB terminal effector pathways (prostaglandins [prostaglandin E2, prostaglandin F2α] and matrix metalloproteinases [MMP-1, MMP-2, MMP-3, and MMP-9]) was investigated in an amniochorion explant system challenged with lipopolysaccharide (LPS) to mimic inflammation. RESULTS AF follistatin and the activin-A to follistatin ratio varied with gestational age, both decreasing toward term (P < .001). Activin-A was up-regulated in AF infection (>2-fold elevation in activin-A to follistatin ratio) correlating directly with severity of inflammation (both P < .001). Activin-A increased prostaglandins, MMP-1, and MMP-9 released by amniochorion (P < .05) to LPS-equivalent levels. Follistatin effectively blunted the prostaglandin response to activin-A and LPS and that of MMPs after activin-A but not after LPS challenge. CONCLUSION Activin-A and follistatin are part of the complex inflammatory response of the gestational sac to infection and modulate effector pathways leading to PTB. The activin-A to follistatin ratio may play a role in determining the clinical phenotype of PTB as preterm labor or PPROM.
Placenta | 2018
Megan McCarthy; Catalin S. Buhimschi; John Hardy; Antonette T. Dulay; Christine Laky; Mert Ozan Bahtyiar; Ramesha Papanna; Guomao Zhao; Irina A. Buhimschi
OBJECTIVE Haptoglobin (Hp) has key immunoregulatory roles that vary with phenotype (Hp1-1, Hp2-1, Hp2-2). Cord blood Hp expression is switched-off in the normal fetus. We hypothesized that in the setting of fetal inflammation placenta becomes inundated with Hp of fetal origin that in turn modulates the output of PGE2 and MMP-9 in a phenotype dependent manner. METHODS Placentas from 40 pregnancies complicated by preterm birth (PTB) (<37 weeks), without (n = 15) or with (n = 25) intra-amniotic infection and histological chorioamnionitis (HCA) were scored for intensity of Hp immunostaining. Hp mRNA levels were evaluated by PCR. Cord blood Hp levels, switch-on status and phenotypes were determined by ELISA and Western blotting. Using a villous trophoblast explant system we investigated if Hp can modulate the release of PGE2 and MMP-9 in the presence or absence of lipopolysaccharide (LPS). RESULTS All cases with HCA had positive Hp immunoreactivity within fetal vascular spaces. Hp staining intensity correlated with cord blood Hp levels and IL-6. Placentas with and without HCA had similar Hp mRNA levels suggesting Hp immunostaining in the fetal spaces is of fetal rather than placental origin. Both Hp1-1 and Hp2-2 up-regulated PGE2 release in the presence of LPS (2-fold over the LPS level, P < .05), without affecting MMP-9 concentrations. CONCLUSIONS Fetal Hp switch-on status, a marker of antenatal exposure to intra-amniotic infection/inflammation, can be reliably established through evaluation of archived placental specimens. In the setting of infection/inflammation, Hp enhances placental PGE2 output thereby supporting the role of the fetus in triggering parturition.
American Journal of Obstetrics and Gynecology | 2013
Christina Duzyj; Irina A. Buhimschi; John Hardy; Megan McCarthy; Guomao Zhao; Sarah N. Cross; Thomas J. Rutherford; Mert Bahtiyar; Catalin S. Buhimschi
American Journal of Obstetrics and Gynecology | 2013
Karen Archabald; Irina A. Buhimschi; Mert Bahtiyar; Antonette T. Dulay; Sonya S. Abdel-Razeq; Christian M. Pettker; Heather S. Lipkind; John Hardy; Megan McCarthy; Guomao Zhao; Vineet Bhandari; Catalin S. Buhimschi
American Journal of Obstetrics and Gynecology | 2013
Megan McCarthy; John Hardy; Antonette T. Dulay; Christine Laky; Ramesha Papanna; Catalin S. Buhimschi; Irina A. Buhimschi
American Journal of Obstetrics and Gynecology | 2013
Unzila Nayeri; Catalin S. Buhimschi; John Hardy; Megan McCarthy; Sarah N. Cross; Guomao Zhao; Katherine Campbell; Mert Bahtiyar; Heather S. Lipkind; Irina A. Buhimschi
American Journal of Obstetrics and Gynecology | 2013
Sami Makaroun; Catalin S. Buhimschi; Guomao Zhao; Megan McCarthy; John Hardy; Antonette T. Dulay; Christine Laky; Irina A. Buhimschi
/data/revues/00029378/v208i1sS/S0002937812019035/ | 2012
Sarah N. Cross; Irina Buhimschi; Christina Duzyj; Lydia Shook; Megan McCarthy; John Hardy; Guomao Zhao; Catalin Buhimschi
/data/revues/00029378/v208i1sS/S0002937812017590/ | 2012
Lydia Shook; Catalin Buhimschi; Antonette T. Dulay; Megan McCarthy; John Hardy; Christina Duzyj; Irina Buhimschi